DexCom, Inc. (DXCM)

US — Healthcare Sector
Peers: PODD  TNDM  ABT  ALGN  SYK  IDXX  VEEV  NOW 

Automate Your Wheel Strategy on DXCM

With Tiblio's Option Bot, you can configure your own wheel strategy including DXCM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol DXCM
  • Rev/Share 10.9686
  • Book/Share 6.5624
  • PB 12.3081
  • Debt/Equity 0.9806
  • CurrentRatio 1.5203
  • ROIC 0.1239

 

  • MktCap 31670482390.0
  • FreeCF/Share 1.4558
  • PFCF 55.4844
  • PE 55.4154
  • Debt/Assets 0.3444
  • DivYield 0
  • ROE 0.2562

 

  • Rating B-
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation DXCM Truist -- Buy -- $102 June 16, 2025
Initiation DXCM Goldman -- Buy -- $104 May 30, 2025
Initiation DXCM Mizuho -- Outperform -- $85 April 10, 2025
Upgrade DXCM Redburn Atlantic Neutral Buy $85 $115 Feb. 3, 2025
Upgrade DXCM Robert W. Baird Neutral Outperform $86 $104 Jan. 16, 2025

News

DexCom Stock Falls Despite Q2 Earnings Beat & 2025 Sales View Raise
DXCM
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Positive

DXCM beats on Q2 earnings and raises 2025 sales guidance, but shares dip as margin pressure dampens investor enthusiasm.

Read More
image for news DexCom Stock Falls Despite Q2 Earnings Beat & 2025 Sales View Raise
Will DXCM Q2 Earnings Reflect U.S. Coverage Expansion & Stelo Impact?
DXCM
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive

DexCom Q2 results are likely to reflect strong growth on the back of coverage by two large PBMs and Stelo traction, driving momentum and market expansion in 2025.

Read More
image for news Will DXCM Q2 Earnings Reflect U.S. Coverage Expansion & Stelo Impact?
DexCom: Delivering Consistent Growth
DXCM
Published: July 21, 2025 by: Seeking Alpha
Sentiment: Positive

DexCom focuses on continuous glucose monitoring systems, with a strong market position and global reach. Q1 results showed 13% revenue growth, beating expectations, though earnings were slightly below consensus. Analysts remain bullish, with most issuing Buy ratings and price targets ranging from $87 to $110 per share.

Read More
image for news DexCom: Delivering Consistent Growth
Are Medical Stocks Lagging DexCom (DXCM) This Year?
DXCM
Published: July 21, 2025 by: Zacks Investment Research
Sentiment: Negative

Here is how DexCom (DXCM) and Amarin (AMRN) have performed compared to their sector so far this year.

Read More
image for news Are Medical Stocks Lagging DexCom (DXCM) This Year?
Why This Beaten-Down Medical Device Stock Could Be Your Best Investment for the Next 5 Years
DXCM
Published: July 20, 2025 by: The Motley Fool
Sentiment: Negative

Medical device specialist DexCom (DXCM -0.33%) has encountered significant headwinds in the past year. The company's financial results haven't been quite up to the market's standards, and broader market volatility caused by President Donald Trump's trade policies isn't helping either.

Read More
image for news Why This Beaten-Down Medical Device Stock Could Be Your Best Investment for the Next 5 Years
Dexcom Unveils Season 4 Roster for Game-Changing NIL Program at Signing Day Camp Hosted by Mark Andrews
DXCM
Published: July 17, 2025 by: Business Wire
Sentiment: Neutral

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of the fourth season of Dexcom U, the company's one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes. This year's Dexcom U roster welcomes 13 new athletes from colleges and universities across the country — including the University of Oregon, San Diego State University, and Northwestern University — representing 12 sports suc.

Read More
image for news Dexcom Unveils Season 4 Roster for Game-Changing NIL Program at Signing Day Camp Hosted by Mark Andrews
DexCom (DXCM) Upgraded to Strong Buy: Here's What You Should Know
DXCM
Published: July 14, 2025 by: Zacks Investment Research
Sentiment: Positive

DexCom (DXCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Read More
image for news DexCom (DXCM) Upgraded to Strong Buy: Here's What You Should Know
Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?
DXCM
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive

Here is how DexCom (DXCM) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.

Read More
image for news Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?
3 Reasons Growth Investors Will Love DexCom (DXCM)
DXCM
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive

DexCom (DXCM) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Read More
image for news 3 Reasons Growth Investors Will Love DexCom (DXCM)
Here's Why DexCom (DXCM) is a Strong Momentum Stock
DXCM
Published: June 27, 2025 by: Zacks Investment Research
Sentiment: Positive

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Read More
image for news Here's Why DexCom (DXCM) is a Strong Momentum Stock
Why DexCom (DXCM) is a Top Growth Stock for the Long-Term
DXCM
Published: June 25, 2025 by: Zacks Investment Research
Sentiment: Positive

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Read More
image for news Why DexCom (DXCM) is a Top Growth Stock for the Long-Term
Johnson Fistel has Commenced an Investigation on Behalf of DexCom, Inc. Shareholders
DXCM
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral

SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, Inc. (NASDAQ: DXCM) for potential breaches of fiduciary duties and violations of the federal securities laws.

Read More
image for news Johnson Fistel has Commenced an Investigation on Behalf of DexCom, Inc. Shareholders
Profit From the Silver Tsunami: Must-Watch Senior Care & Aging Stocks
ABBV, AMGN, BSX, DXCM
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive

BSX, ABBV, AMGN and DXCM are tapping into the aging boom with cutting-edge tech, chronic care drugs and senior-focused innovations.

Read More
image for news Profit From the Silver Tsunami: Must-Watch Senior Care & Aging Stocks
Here's Why You Should Add DexCom Stock to Your Portfolio Now
DXCM
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive

DXCM continues to raise investor optimism due to its strong product portfolio.

Read More
image for news Here's Why You Should Add DexCom Stock to Your Portfolio Now
5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil
CLPT, DXCM, FMS, IDXX, NPCE
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive

Five high-flying medical instrument stocks are: DXCM, IDXX, NPCE, CLPT, FMS.

Read More
image for news 5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil
Top Health & Fitness Stocks to Buy for the Wellness Boom
DXCM, HIMS, SFM
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Positive

The health and fitness boom is fueling demand for gyms, nutrition, and wellness services. Stocks like SFM, HIMS and DXCM are well-positioned to benefit.

Read More
image for news Top Health & Fitness Stocks to Buy for the Wellness Boom
All You Need to Know About DexCom (DXCM) Rating Upgrade to Buy
DXCM
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive

DexCom (DXCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Read More
image for news All You Need to Know About DexCom (DXCM) Rating Upgrade to Buy
Buy 5 Health and Fitness Stocks to Enhance Your Portfolio Returns
DXCM, GDRX, HIMS, SFM, UNFI
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive

Five Health and Fitness stocks to buy now are: SFM, DXCM, HIMS, UNFI, GDRX.

Read More
image for news Buy 5 Health and Fitness Stocks to Enhance Your Portfolio Returns
DexCom Q1 Earnings: Organic Revenue Growth Versus Cost Pressure
DXCM
Published: May 09, 2025 by: Seeking Alpha
Sentiment: Neutral

DexCom's Q1 2025 earnings show strong growth potential, but cost pressures are impacting margins, leading me to lower my rating from buy to hold. Despite demographic tailwinds and a growing market, gross margin declines and cost pressures present significant downside risks. My updated DCF analysis yields a price target of $92.90 for DXCM stock, only a 9% upside from current prices, reducing the margin of safety.

Read More
image for news DexCom Q1 Earnings: Organic Revenue Growth Versus Cost Pressure
DexCom Stock: Earnings Beat and New Market Access Drive Bull Case
DXCM
Published: May 08, 2025 by: MarketBeat
Sentiment: Positive

DexCom, Inc. NASDAQ: DXCM has once again demonstrated its formidable position in the continuous glucose monitoring (CGM) market, delivering outstanding first-quarter 2025 financial results that underscore its sustained momentum. The company's performance, driven by strong product demand, successful innovation, and strategic market access expansion, strongly supports an ambitious trajectory for the remainder of 2025, indicating a clear path towards further solidifying its leadership in diabetes technology.

Read More
image for news DexCom Stock: Earnings Beat and New Market Access Drive Bull Case
5 Best Stocks of the S&P 500 ETF in the Past Month
DXCM, GEV, NFLX, PLTR, PWR
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive

The S&P 500 is enjoying its longest winning streak since 2004. We have highlighted the five best stocks in the S&P 500 over the past month.

Read More
image for news 5 Best Stocks of the S&P 500 ETF in the Past Month
DexCom Stock Rises Despite Q1 Earnings Miss & Lower Margins
DXCM
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Positive

DXCM's first-quarter 2025 earnings decline despite increasing sales. Its performance in 2025 is expected to be fueled by global growth in CGM adoption, strong Sensor sales and expansion into new markets.

Read More
image for news DexCom Stock Rises Despite Q1 Earnings Miss & Lower Margins
Nasdaq Index: Dexcom, Meta, ON Semi Lead US Stocks Rebound on Trade Optimism
DXCM, META, ON
Published: May 02, 2025 by: FXEmpire
Sentiment: Positive

Nasdaq jumps as Dexcom, Palantir, and ON Semi soar. Jobs report beats forecasts, easing inflation fears and driving US stock market optimism.

Read More
image for news Nasdaq Index: Dexcom, Meta, ON Semi Lead US Stocks Rebound on Trade Optimism
Dexcom Stock Is Today's Big Winner After Earnings. Why the Medtech Is Soaring.
DXCM
Published: May 02, 2025 by: Barrons
Sentiment: Positive

Dexcom, the maker of glucose monitors for patients with diabetes, reports a strong first quarter.

Read More
image for news Dexcom Stock Is Today's Big Winner After Earnings. Why the Medtech Is Soaring.
MedTech Stocks' Earnings to Watch on May 1: BDX, CAH, BAX, DXCM & SYK
BAX, BDX, CAH, DXCM, SYK
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive

This earnings season so far has reflected a continued recovery in sales for companies within the Medical sector. Earnings have increased year over year, albeit at a slower pace than revenues.

Read More
image for news MedTech Stocks' Earnings to Watch on May 1: BDX, CAH, BAX, DXCM & SYK
DexCom Shares May Rise as G7 15-Day CGM System Gets FDA Clearance
DXCM
Published: April 11, 2025 by: Zacks Investment Research
Sentiment: Positive

DXCM secures FDA clearance for its G7 15-Day CGM, the longest-lasting and most accurate wearable, enhancing user convenience and expanding diabetes care access.

Read More
image for news DexCom Shares May Rise as G7 15-Day CGM System Gets FDA Clearance
FDA Approves Dexcom's 15-Day Wearable Glucose Management System. Company Plans US Launch
DXCM
Published: April 10, 2025 by: Benzinga
Sentiment: Positive

The U.S. Food and Drug Administration approved DexCom, Inc.'s DXCM Dexcom G7 15-Day Continuous Glucose Monitoring System for people over 18 with diabetes.

Read More
image for news FDA Approves Dexcom's 15-Day Wearable Glucose Management System. Company Plans US Launch
DexCom Stock Rises as Glucose Monitoring System Gets FDA Clearance
DXCM
Published: April 10, 2025 by: Barrons
Sentiment: Positive

DexCom says its G7 15 Day system will land on the market in the second half of 2025.

Read More
image for news DexCom Stock Rises as Glucose Monitoring System Gets FDA Clearance
Nanowear Announces Continuous Glucose Monitoring (CGM) Licensing and Data Partnership With Dexcom
DXCM
Published: March 25, 2025 by: Business Wire
Sentiment: Neutral

NEW YORK--(BUSINESS WIRE)--Nanowear, a leader in home-based cardiometabolic digital diagnostics announced that SimpleSense™, a nanotechnology-enabled wearable, mobile and software diagnostics platform, will ingest glucose data from Dexcom G7 Continuous Glucose Monitoring Systems (CGM) time synchronously alongside Nanowear's previously FDA cleared cardiovascular biomarkers. The continuous combination of glucose readings, blood pressure, ECGs, lung volume, respiration and hemodynamics offer unpre.

Read More
image for news Nanowear Announces Continuous Glucose Monitoring (CGM) Licensing and Data Partnership With Dexcom
DexCom CGM Sensor Sales to Continue Despite FDA Warning Letter
DXCM
Published: March 14, 2025 by: Zacks Investment Research
Sentiment: Negative

DXCM faces an FDA warning over manufacturing issues, but operations remain unaffected. However, supply-chain risks and rising competition pose challenges.

Read More
image for news DexCom CGM Sensor Sales to Continue Despite FDA Warning Letter

About DexCom, Inc. (DXCM)

  • IPO Date 2005-04-14
  • Website https://www.dexcom.com
  • Industry Medical - Devices
  • CEO Kevin Ronald Sayer
  • Employees 10200

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.